{"filings":[{"id":91857,"accession_number":"0001274737-26-000027","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose 12% YoY to $17.3M; net loss widened to $4.0M from $3.8M.","AVISE CTD test volume increased 10% YoY; TTM ASP rose 6% to $444.","Adjusted EBITDA loss improved 14% to $2.2M; cash $21.5M, ahead of expectations.","Full-year 2026 revenue guidance reaffirmed at $70M-$73M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":17306000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91856,"accession_number":"0001274737-26-000015","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Ana Hooker resigns from Exagen board, effective April 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ana Hooker resigned as director and chair of Nominating and Corporate Governance Committee, also member of Audit Committee.","Resignation was not due to any disagreement with Exagen on operations, policies, or practices.","Board size reduced from 8 to 7 members effective April 17, 2026.","Paul Kim, Scott Kahn, Bruce Robertson, Frank Stokes, Charles McKhann remain with updated committee assignments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102237,"accession_number":"0001274737-26-000007","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY 2025 revenue of $66.6M, up 20% YoY; guides FY 2026 revenue $70-73M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $66.6M (+20% YoY); Q4 2025 revenue $16.6M.","Full-year net loss $19.95M; adjusted EBITDA loss $9.79M; gross margin 58.3%.","AVISE CTD test volume grew >11% YoY; trailing 12-month ASP rose to $441 (+7%).","FY 2026 revenue guidance of $70M to $73M; path to cash flow positivity.","Year-end cash $32.4M; strengthened by $20M equity offering and $25M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102236,"accession_number":"0001274737-26-000003","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exagen reports record 2025 revenue $66-67M, up 19-20% YoY; cash at $32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $16-17M (17-24% YoY growth); full-year revenue $66-67M (19-20% YoY growth).","AVISE CTD volume 136,000-137,000 (+11% vs 2024); TTM ASP $441-$445, up >$30 from 2024.","Year-end cash $32M, up $10M from 2024; results in line with prior guidance.","CEO cites topline growth from volume and ASP expansion; new AVISE platform enhancements launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":66575000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118540,"accession_number":"0001274737-25-000069","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 revenue $17.2M (+38% YoY), record; net loss $7.1M; guides FY rev $65-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.2M up 38% YoY; net loss $7.1M vs $5.0M loss last year.","Adjusted EBITDA loss narrowed to $1.9M from $4.0M; gross margin improved to 58.4%.","AVISE CTD test volume up 16% YoY; ASP $441 (+$37 YoY).","Cash at $35.7M, up from $30.0M in Q2 2025.","FY2025 revenue guidance $65-70M; expects positive adjusted EBITDA in Q4 at high end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":49944000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135013,"accession_number":"0001274737-25-000061","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.","Net loss $4.4M vs $3.0M in Q2 2024; operating loss $2.6M, roughly flat; adjusted EBITDA -$1.7M.","Cash $30.0M after $20.2M public offering and new credit facility; ASP $428, up $27 YoY.","FY 2025 revenue guidance $65M-$70M; expects positive adjusted EBITDA in Q4 at high end.","Appointed Dr. Michael Mahler as CSO; added Chas McKhann to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":32700000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135012,"accession_number":"0001274737-25-000055","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints former Silk Road Medical CEO Chas McKhann to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chas McKhann appointed Class III director effective July 17, 2025; term expiring at 2028 annual meeting.","Previously served as President/CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific.","Board size increased from 7 to 8 members; McKhann also joins Compensation and Nominating Committees.","McKhann received 7,500 RSUs vesting over 4 years; annual option for 9,000 shares under amended compensation plan.","Board approved amended non-employee director compensation program effective July 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151959,"accession_number":"0001274737-25-000036","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Aballi re-elected with 8.59M votes; Bruce Robertson re-elected with 5.66M votes for three-year terms.","BDO USA ratified as auditor for FY2025 (11.53M for, 74,611 against).","Advisory vote on executive compensation approved (8.60M for); frequency set at 1 year (8.38M for).","Broker non-votes of ~3.0M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151958,"accession_number":"0001193125-25-116881","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exagen closes $20.2M public offering at $5.25/share; net proceeds ~$18.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,350,000 shares plus full exercise of underwriter's option for 502,500 shares.","Gross proceeds of ~$20.2M; net proceeds after fees and expenses ~$18.6M.","Canaccord Genuity acted as sole bookrunner; offering priced at $5.25 per share.","Shares sold under effective shelf registration; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151957,"accession_number":"0001193125-25-115946","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Exagen prices public offering of 3.35M shares at $5.25/share for ~$17.6M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,350,000 shares priced at $5.25; gross proceeds $17.6M; net expected ~$16.2M after expenses.","Underwriter Canaccord Genuity has a 30-day option to buy up to 502,500 additional shares.","Offering expected to close May 9, 2025; proceeds for working capital and general corporate purposes.","All shares sold by Exagen; no binding acquisition agreements at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151956,"accession_number":"0001274737-25-000023","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 revenue record $15.5M, but net loss widens to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.5M (+7.5% YoY); net loss $(3.8)M vs $(3.4)M; adjusted EBITDA $(2.5)M vs $(2.0)M.","Trailing-12-month ASP rose to $419 from $377; AVISE CTD test volume grew.","FY2025 guidance: revenue at least $65M; targeting positive adjusted EBITDA in Q4 2025.","Closed $25M senior secured credit facility with Perceptive Advisors on April 25, 2025.","Combined cash and AR projected ~$28M as of April 30 after releasing held claims."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":15498000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151955,"accession_number":"0001193125-25-100447","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Exagen secures up to $75M term loan from Perceptive; $25M funded to retire existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M funded at closing used to retire Innovatus debt; net proceeds ~$22.8M after costs.","Additional tranches: $10M (by Mar 2026), $10M (by Dec 2026), $30M (BD by Mar 2027) subject to revenue milestones.","Interest: Term SOFR + 7% (floor 4.75%), interest-only for 60 months, maturity April 25, 2030.","Warrants for 400k shares issued at close (exercise $4.96/$5.58); up to 750k more for future tranches.","Loan secured by substantially all assets; covenants include $3M min cash and quarterly net revenue targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170801,"accession_number":"0001274737-25-000018","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY 2024 revenue of $55.6M; guides Q1 2025 revenue ≥$14.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $13.655M; gross margin 62.1%; FY revenue $55.641M, up from prior year.","AVISE CTD trailing 12-mo ASP reached $411, a $75 increase per test.","FY net loss improved ~$8M YoY to ($15.1M); adjusted EBITDA loss improved ~$7M to ($10.1M).","Surpassed 1 million patients tested with AVISE CTD; launched new SLE and RA biomarker assays in Jan 2025.","Expects positive adjusted EBITDA in Q4 2025; Q1 2025 revenue at least $14.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170800,"accession_number":"0001274737-25-000003","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.","Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).","AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.","Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.","CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":55641000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187772,"accession_number":"0001274737-24-000091","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.","AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.","Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.","Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.","Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":41986000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204278,"accession_number":"0001274737-24-000078","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen posts record Q2 revenue $15.1M, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue of $15.1M in Q2 2024, up from $14.1M in Q2 2023.","Net loss improved 40.8% to $3.0M; adjusted EBITDA loss improved 53.5% to $1.6M.","Gross margin expanded to 60.1% from 58.7% YoY.","AVISE CTD trailing 12-month ASP reached $401, up 25.3% YoY.","Company raised full-year 2024 revenue and adjusted EBITDA guidance (specific figures not disclosed in release)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":29479000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204277,"accession_number":"0001274737-24-000071","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.","John Aballi serves as interim CFO from July 31 until Black's start.","Black receives $460K base salary, $125K signing bonus, and up to 225K RSUs.","Black previously CFO at Standard BioTools, Apollo Endosurgery, and Alphatec Spine.","Adawi entitled to severance as Tier 2 participant under company's severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204276,"accession_number":"0001274737-24-000074","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K/A","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Jeffrey Black as CFO effective Sept 1, John Aballi interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kamal Adawi terminated as CFO and Corporate Secretary effective August 1, 2024.","John Aballi named interim CFO and principal financial officer pending Black's start.","Jeffrey Black to become CFO on Sept 1, 2024; base salary $460K, signing bonus $125K.","Black receives RSUs for 225,000 shares vesting over 4 years, target bonus 50% of salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221022,"accession_number":"0001274737-24-000056","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exagen stockholders elect three Class II directors and ratify BDO USA as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ana Hooker, Paul Kim, Frank Stokes elected as Class II directors for three-year term expiring 2027.","Kim received 8,037,137 votes for; Hooker 7,720,706; Stokes 7,970,534; broker non-votes 3,839,742 each.","Ratification of BDO USA as independent auditor passed with 11,798,192 for, 19,271 against, 81,801 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221021,"accession_number":"0001274737-24-000045","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.","Net loss $3.4M, a 56.3% improvement; adjusted EBITDA -$2.0M, a 67.7% improvement.","AVISE CTD trailing 12-month ASP $377, up 35.1% versus prior year.","Company raises full-year 2024 revenue and adjusted EBITDA guidance on strong momentum.","Cash and equivalents $27.3M; accounts receivable $10.9M; cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":14415000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221020,"accession_number":"0001274737-24-000030","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exagen appoints Scott Kahn to board; three directors resign, board size reduced to 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Brian Birk, Wendy Johnson, and Ebetual Pallares to resign effective June 10, 2024; no disagreements cited.","Scott D. Kahn, Ph.D. appointed as Class I director effective June 10, 2024; serves on Compensation and Nominating Committees.","Board size decreases from 9 to 7 members at the effective date.","Dr. Kahn brings 30+ years life sciences experience, including former CIO at Illumina and Chief Information/Privacy Officer at LunaPBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240602,"accession_number":"0001274737-24-000019","cik":1274737,"company_name":"EXAGEN INC.","ticker":"XGN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exagen reports record FY2023 revenue of $52.5M; net loss narrows to $23.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record full-year revenue $52.5M (+10% YoY); Q4 revenue $13.8M (+8% YoY)","Record 137,650 AVISE CTD tests performed in 2023; trailing 12-month ASP rose to $336","Gross margin improved to 56% for FY2023 (59% Q4) from 44% in FY2022","Net loss $23.7M for FY2023 vs $35.1M in FY2022; adjusted EBITDA -$17.1M vs -$29.1M","Cash balance $36.5M at year-end; management cites progress toward profitability"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90120000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}